A case report of a woman with relapsing-remitting multiple sclerosis (RRMS) who developed shingles while being treated with dimethyl fumarate (Tecfidera) has raised questions of whether the drug reactivates the varicella-zoster virus.
Wednesday, April 20, 2016
Doctors Study Possible Link Between Tecfidera (Dimethyl Fumarate) and Shingles
A case report of a woman with relapsing-remitting multiple sclerosis (RRMS) who developed shingles while being treated with dimethyl fumarate (Tecfidera) has raised questions of whether the drug reactivates the varicella-zoster virus.
Thursday, April 7, 2016
MS Therapy Tecfidera Might Exert its Actions by Increasing B-cells
While treatment of relapsing-remitting multiple sclerosis (RRMS) with Tecfidera (dimethyl fumarate) keeps relapse rates low, the details of immune changes induced by the drug are still evading scientists. A new study reported that the treatment increases the number of regulatory B-cells (Bregs), presenting a potential marker of treatment response.
Tecfidera (Dimethyl Fumarate) in Children with MS: A Dual-Center Study: STUDY
Image Source: MSVIEWSANDRELATEDNEWS
Tecfidera Seen to Alter Anti-Inflammatory Profile in Immune Cells
Study looks at mode of action in a relatively new, delayed-release treatment for RRMS
Delayed-release dimethyl fumarate (Tecfidera) was recently approved for patients with relapsing-remitting multiple sclerosis (RRMS), although the mechanisms by which the drug exerts its action were not fully understood. A new study from the University Hospital Münster, Germany, shows that dimethyl fumarate alters the balance between subpopulations of T-cells to promote a more anti-inflammatory state.
Disease-modifying treatments for MS – a review of approved medications: STUDY
Image Source: THEBRINLEYFAMILY
New MS Drug Therapy Based on Monomethyl Fumarate Moving Along in Testing
Alkermes enrolling MS patients to assess safety of ALKS 8700 (MMF) compared to Tecfidera
Alkermes plc, a biopharmaceutical company focused on therapies for the treatment of central nervous system (CNS) disorders, announced that it has successfully met its 2015 goals for their product and late-stage pipeline drug portfolio, including ALKS 8700, a monomethyl fumarate (MMF) drug candidate for the treatment of multiple sclerosis (MS).
MS drugs to receive funding
Tecfidera capsules and Aubagio tablets will be state-funded from February 1. Photo / iStock
Two more medicines will be funded by taxpayers for the treatment of multiple sclerosis, following a decision by Government agency Pharmac.
Alkermes’ MS Therapy ALKS 8700 Yields Positive Clinical Trial Data
Image Source: MULTIPLESCLEROSISNEWSTODAY
Alkermes plc, a fully integrated global biopharmaceutical company, recently provided a regulatory update and positive clinical trial data for ALKS 8700, an oral, innovative and proprietary monomethyl fumarate (MMF) compound that is being developed to treat multiple sclerosis (MS).
New Data Show Strong, Sustained Effects of TECFIDERA® (Dimethyl Fumarate) in Newly-Diagnosed and Early Disease Course MS Patients
Biogen will present new data that reinforce the proven efficacy and well-established safety profile of TECFIDERA® (dimethyl fumarate) in a broad range of people with relapsing-remitting multiple sclerosis (RRMS) at the 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Barcelona, Spain (7-10 October). The data show that TECFIDERA significantly reduced multiple sclerosis (MS) relapses and delayed disability progression in patients who are newly diagnosed and those early in their disease course; these effects were sustained over six years of follow-up.
Biogen to Highlight Broad Research Commitment to MS Care at ECTRIMS Congress, Including New TECFIDERA® Data Demonstrating Importance of Early Treatment
Biogen (BIIB) will present new clinical data for its multiple sclerosis (MS) portfolio of therapies, including the most-prescribed oral treatment, TECFIDERA® (dimethyl fumarate), at the 31st meeting of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Barcelona, Spain, 7-10 October 2015.1 TECFIDERA data will demonstrate its strong and sustained efficacy in relapsing-remitting multiple sclerosis (RRMS) among patients who were early in the course of their disease or newly diagnosed.
Biogen Inc (BIIB) Tecfidera PML Risk Unlikely To Affect Sales: Merrill Lynch: VIDEO
Merrill Lynch analysts Ying Huang and Catherine Hu commented on the future prospects of Biogen Inc (NASDAQ:BIIB) in a research report dated September 21. They maintain a Buy rating on the stock, with a price target of $400, signifying a return potential of more than 27% over Friday’s close at $314.67 apiece.
Switching from Tysabri to Tecfidera: VIDEO
Dr. Daniel Kantor talks about switching from Tysabri to Tecfidera and the outcomes.
Click here to see more
Pegylated Interferon Beta-1a for Multiple Sclerosis: VIDEO
The MD Magazine Peer Exchange "Modifying the Course of Multiple Sclerosis in New Ways: The Latest Advances in Treatment" features a distinguished panel of physician experts discussing key topics in multiple sclerosis (MS) research and management, including the latest insights into MS pathophysiology, new medication options and their application in clinical practice, and more.
Biogen's Tecfidera And Other Orals Benefit As Increasingly Risk-Tolerant Neurologists Seek To Arrest Multiple Sclerosis (MS) Progression Sooner
Image source: MULTIPLESCLEROSIS.NET
UG, Switzerland, Aug. 13, 2015 /PRNewswire/ -- Feedback gathered from 97 neurologists in June reveals that growing comfort with oral disease-modifying agents (DMAs) as well as multiple years of patient experience is driving neurologists to leave the injectables behind. While experience benefits oral agents moving forward in the treatment armamentarium, it is not the same story for established products such as Biogen's infused agent, Tysabri, which remains relegated further back in the treatment journey.
Biogen’s Tecfidera Now The Most Prescribed Oral MS Therapy Globally
Cambridge, Massachusetts based Biogen Inc. has reported its second quarter 2015 results, posting a year-over-year seven percent revenue increase to $2.6 Billion in the quarter.
Subscribe to:
Posts (Atom)